Asia Beat: Alliances take centre stage as companies pursue growth
This article was originally published in Scrip
If there was one word to sum up the pharma business news out of Asia over the past few weeks it was "alliance", be it to gain access to the US oncology sector, the generics market in Japan or to promote older drugs in South Korea.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.